Teva Pharmaceuticals
TEVA
452 hedge funds and large institutions have $5.92B invested in Teva Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 46 funds opening new positions, 159 increasing their positions, 138 reducing their positions, and 111 closing their positions.
15% more repeat investments, than reductions
Existing positions increased: 159 | Existing positions reduced: 138
2.88% less ownership
Funds ownership: 61.63% → 58.75% (-2.9%)
13% less funds holding
Funds holding: 522 → 452 (-70)
18% less call options, than puts
Call options by funds: $255M | Put options by funds: $309M
44% less capital invested
Capital invested by funds: $10.5B → $5.92B (-$4.61B)
46% less funds holding in top 10
Funds holding in top 10: 13 → 7 (-6)
59% less first-time investments, than exits
New positions opened: 46 | Existing positions closed: 111
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$86.3M |
| 2 |
Morgan Stanley
New York
|
+$62M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$53.5M |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$48.6M |
| 5 |
Nuveen
Charlotte,
North Carolina
|
+$42.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$132M |
| 2 |
BC
Brahman Capital
New York
|
-$111M |
| 3 |
PCM
Polaris Capital Management
Boston,
Massachusetts
|
-$91.5M |
| 4 |
Capital World Investors
Los Angeles,
California
|
-$84.7M |
| 5 |
HCM
Highfields Capital Management
Boston,
Massachusetts
|
-$83M |
TEVA Hedge Fund Activity: Q2 2019 in Review
452 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceuticals (TEVA) for Q2 2019, worth a combined $5.92B — down 44% from $10.5B a quarter earlier.
Sellers outnumbered buyers: 111 funds closed out of TEVA and 46 opened new positions — a net loss of 65 holders — while 138 trimmed existing stakes and 159 added.
The largest buyer was Renaissance Technologies, adding an estimated $86.3M. The largest seller was Fidelity Investments, cutting an estimated $132M.
- 452 institutional investors held Teva Pharmaceuticals (TEVA) as of Q2 2019, down from 522 in Q1 2019.
- Funds reported $5.92B of Teva Pharmaceuticals stock for Q2 2019, down 44% quarter-over-quarter.
- 46 funds opened new Teva Pharmaceuticals positions in Q2 2019 and 111 closed out, a net change of -65 holders.
- The largest Teva Pharmaceuticals buyer in Q2 2019 was Renaissance Technologies, an estimated $86.3M added.
- The largest Teva Pharmaceuticals seller in Q2 2019 was Fidelity Investments, an estimated $132M sold.
Based on aggregated 13F filings for Q2 2019.